Bio/Pharma Business

As Europe’s bio/pharma market learns that breaking up is hard to do, it also must address productivity, regulatory, and drug pricing challenges.

Rookie API developers beat pharma at its own game.

Survey reveals optimism, discontent, and a desire for better career opportunities.

Europe-based bio/pharma employees are unified on satisfaction with employment conditions-and dissatisfaction with salaries.

Biopharma proponents argue for FDA resources, Cures legislation, and science-based drug regulation.

Steep price increases for a popular drug have created patient and Congressional backlash.

A KPMG survey reveals that approximately 84% of pharma and medical device executives plan to add jobs in next 12 months.

PharmTech’s 2016 survey shows general satisfaction with existing solid-dose and parenteral manufacturing equipment, and slow adoption of continuous manufacturing processes.

Quality, innovation, and new approval pathways open drug development options for the Chinese market, including injectable contract manufacturing.

Patheon launches initial public offering to repay outstanding notes and expenses.

CPhI Pharma Awards seek nominations for excellence in development and manufacturing.

Investment in talent and infrastructure, more quality-by-design skills, and increased communication with global regulators will be needed to combat compliance issues at API and drug manufacturing facilities in India.

Insight on the new regulatory framework from the China Food and Drug Administration

PharmTech sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.

AMRI’s acquisition of Euticals expands its API development and manufacturing business.

Policies for patient access to life-saving therapies must keep pace with biomedical innovation.

Immuno-oncology drugs are demonstrating patient benefits, but growing resistance to the high cost has implications for patients, market access, and manufacturers.

By focusing on laying strong technology foundations, pharmaceutical businesses can make informed decisions, equip themselves with the capabilities to eliminate threats, and future-proof operations.

At DCAT 2016, IMS Health economist Graham Lewis noted that pharma is reliving trends last seen in the 1980s. Despite value-based medicine, he said, the blockbuster model is alive and well.

Collaboration will provide for unified development and manufacture of antibody drug conjugates.

Generic drugs, market access, and foreign manufacturing are conference topics at CPhI Japan 2016.

Wyeth reaches agreement in principle to resolve Medicaid drug rebate claims for 2001-2006 period for Protonix.

Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction.

Suppliers must develop new technologies to drive the bio/pharma innovation engine.

Infrastructure and payer decisions will determine drug choices in emerging and developed regions.

Amid corporate restructurings, regulatory initiatives, and aging R&D assets, will drug development accelerate or stall in 2016?

Regulatory, corporate restructuring, and manufacturing issues will challenge bio/pharma to meet the needs and expectations of patients around the world.

The use of drug compounding facilities to produce over-priced generic drugs raises quality and regulatory questions.

Employers have work to do to improve job satisfaction and retain qualified workers.

Bio/pharma employee dissatisfaction with pay and progress may direct some to new career pathways.